Financial Performance - The company's operating revenue for 2020 was ¥2,441,451,789.23, a decrease of 0.32% compared to 2019[28]. - Net profit attributable to shareholders for 2020 was ¥473,739,388.42, an increase of 2.19% year-over-year[28]. - The net cash flow from operating activities increased by 17.36% to ¥752,501,253.68 in 2020[28]. - The total assets at the end of 2020 were ¥4,923,573,835.05, reflecting a growth of 3.45% from the previous year[28]. - Basic earnings per share for 2020 were ¥0.75, up 1.35% from ¥0.74 in 2019[28]. - The weighted average return on equity decreased by 0.89 percentage points to 12.74% in 2020[28]. - The company achieved a net profit attributable to the parent company of 474 million yuan, an increase of 10 million yuan, representing a growth of 2.19% compared to the same period last year[43]. - The company reported a net profit of ¥131,424,924.09 in Q1 2020, with a total revenue of ¥525,279,630.39 for the same quarter[30]. Dividend Distribution - The proposed cash dividend distribution is 2.7 RMB per 10 shares, totaling 170.1 million RMB, which accounts for 35.91% of the net profit attributable to shareholders[6]. - In 2020, the company distributed cash dividends of RMB 170.1 million, which is 35.91% of the net profit attributable to shareholders of RMB 473.74 million[163]. - In 2019, the cash dividends amounted to RMB 157.5 million, representing 33.97% of the net profit of RMB 463.60 million[163]. - In 2018, the cash dividends were RMB 147 million, which is 31.26% of the net profit of RMB 470.25 million[163]. - The company has adhered to the cash dividend policy as per regulatory guidelines and has maintained a stable cash dividend plan[163]. - The company did not propose a cash profit distribution plan for the reporting period despite having positive distributable profits[166]. Audit and Compliance - The company has received a standard unqualified audit report from Ernst & Young Huaming[5]. - The board of directors and supervisory board members have all attended the board meeting[5]. - The company has appointed Ernst & Young Huaming as its domestic accounting firm[27]. - The company reported no major litigation or arbitration matters during the reporting period, reflecting a stable legal standing[180]. - The company has not faced any risks of suspension or termination of its listing, indicating compliance with regulatory requirements[180]. - The company has not made any changes to its accounting policies or estimates during the reporting period, ensuring consistency in financial reporting[179]. Market and Industry Trends - The pharmaceutical industry in China generated revenue of 2,485.73 billion yuan in 2020, with a year-on-year growth of 4.5%[44]. - The pharmaceutical industry is facing challenges such as price reductions and increased market concentration, necessitating strategic adaptations[44]. - The pharmaceutical industry is experiencing a slowdown in overall growth, with increased market concentration and intensified competition due to price reductions and policy reforms[96]. - The demand for the pharmaceutical industry is expected to continue growing due to an aging population and increasing healthcare expenditures, which have risen from 4.9% of GDP in 2003 to 6.6% in 2019[96]. Product Development and Innovation - The company launched new health products in 2020, including probiotics and disinfectant wipes[39]. - The company emphasizes the integration of traditional Chinese medicine theory with modern scientific research to drive product innovation[51]. - The company is focusing on transitioning from a "small and beautiful" model to a "large and strong" development strategy in its 14th Five-Year Plan[59]. - The company is actively developing special medical purpose foods and conducting related research[123]. - The company focused on the development of traditional Chinese medicine products, including classic prescriptions and health products such as probiotics and functional peptides[127]. - The company is committed to developing innovative health products and accelerating the integration of online and offline channels, targeting the "Z generation" for marketing[155]. Strategic Initiatives - The company is expanding its e-commerce sales channels, currently focusing on platforms like Tmall, JD.com, and Pinduoduo[50]. - The company plans to enhance its non-prescription drug business by expanding its gastrointestinal product line and launching new children's products[151]. - The company intends to solidify its existing prescription drug market while covering previously weak markets, focusing on academic promotion and clinical product revitalization[154]. - The company aims to adapt to policy directions to promote the development of new traditional Chinese medicine products[109]. - The company is preparing for the potential impacts of volume-based procurement on traditional Chinese medicine products[108]. Research and Development - Research and development expenses increased by 16.93% to 55.55 million RMB compared to the previous year[64]. - R&D investment represented 2.38% of total revenue, with 246 R&D personnel making up 6.47% of the workforce[87]. - The company invested 375.26 million RMB in the efficacy study of earthworm enzyme, showing a significant increase of 1,822.07% compared to the previous year[131]. - The R&D investment for the classic Chinese medicine product development was 307.35 million RMB, reflecting a 150.50% increase year-on-year[131]. Social Responsibility and Community Engagement - The company invested a total of 820,000 RMB in poverty alleviation efforts, successfully reducing the poverty incidence from 4.97% to 0% in the supported village[194]. - The company facilitated the introduction of new agricultural businesses, generating over 80,000 RMB in additional income for the village collective economy[196]. - The company organized 12 committee meetings and 12 branch meetings to enhance party organization and responsibility in poverty alleviation efforts[196]. - The company has improved public infrastructure in impoverished areas, addressing issues such as transportation, healthcare, electricity, and drinking water[196]. - Total funding for poverty alleviation amounted to 800,000 RMB, with 49 individuals lifted out of poverty[197]. Risk Management - The company faces risks related to raw material prices and supply, particularly for traditional Chinese medicine materials, and will implement strategies to monitor and control costs[158]. - The company is addressing uncertainties related to the pandemic by accelerating marketing, R&D, and new product launches to mitigate operational risks[161]. - The company recognizes the risk of intensified competition in the OTC market due to the growth of internet healthcare and will strengthen brand building and digital marketing capabilities[157].

Financial Performance - Net profit attributable to shareholders of the listed company was ¥398,040,367.58, reflecting a year-on-year increase of 4.30%[17] - Operating income for the first nine months was ¥1,735,158,093.44, up 1.85% from the same period last year[17] - The net cash flow from operating activities for the first nine months was ¥714,502,701.39, an increase of 11.35% year-on-year[17] - Total operating revenue for Q3 2020 was CNY 576,696,483, an increase from CNY 562,694,201 in Q3 2019, representing a growth of 2.0%[72] - Net profit for Q3 2020 was CNY 131,840,980.81, slightly down from CNY 133,499,477.02 in Q3 2019, a decrease of 1.2%[75] - Total comprehensive income attributable to the parent company for the first three quarters of 2020 was approximately ¥398.04 million, up from ¥381.64 million in the same period of 2019[77] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,793,102,378.24, an increase of 0.71% compared to the end of the previous year[17] - Current liabilities decreased to ¥543,858,700.26 from ¥748,912,845.10, a reduction of approximately 27.4%[61] - Total liabilities decreased to ¥621,326,102.28 from ¥834,837,147.96, a reduction of approximately 25.6%[63] - Total equity increased to ¥4,171,776,275.96 from ¥3,924,356,609.29, reflecting a growth of about 6.3%[63] Revenue Breakdown - Revenue from over-the-counter drugs was ¥1,356,244,387.59, with a year-on-year increase of 2.52%[23] - Revenue from prescription drugs was ¥253,000,999.78, showing a year-on-year decrease of 9.89%[23] - Revenue from the East China region was ¥514,027,424.91, an increase of 7.16% compared to the previous year[24] Cash Flow and Investments - The company's cash and cash equivalents at the end of the period amounted to 291 million RMB, a decrease of 637 million RMB or 68.65% compared to the end of the previous year, primarily due to the investment in bank principal-protected financial products[27] - The net cash flow from investing activities was -1.188 billion RMB, an increase in outflow of 652 million RMB compared to the same period last year, primarily due to the purchase of bank financial products[29] - The net cash flow from operating activities for Q3 2020 was CNY 715,185,378.15, an increase from CNY 599,368,225.16 in Q3 2019, reflecting a growth of about 19.4%[89] Research and Development - Research and development expenses for Q3 2020 amounted to CNY 10,932,375.89, up from CNY 9,840,382.47 in Q3 2019, indicating an increase of 11.1%[72] - Research and development expenses increased to ¥10.93 million in Q3 2020, up 11.1% from ¥9.84 million in Q3 2019[80] Shareholder Information - The company reported a total of 44,593 shareholders at the end of the reporting period[24] - The company has no related party or concerted action relationships with the top ten shareholders, with the controlling shareholder being China Resources Jiangzhong Pharmaceutical Group[27] Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[75]

Financial Performance - The company's operating revenue for the first half of 2020 was RMB 1,158,461,610.44, representing a 1.54% increase compared to RMB 1,140,918,626.22 in the same period last year[20]. - Net profit attributable to shareholders reached ¥270,002,490.49, an increase of 7.14% compared to the previous year[23]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥266,370,628.12, reflecting a 13.41% increase year-on-year[23]. - Basic earnings per share rose to ¥0.43, a 7.50% increase from the previous year[23]. - Diluted earnings per share also increased to ¥0.43, marking a 7.50% rise year-on-year[23]. - Operating cash flow net amount increased by 45.72% to ¥690,545,105.25 compared to the same period last year[23]. - The company's operating revenue for the current period is approximately ¥1.16 billion, an increase of 1.54% compared to ¥1.14 billion in the same period last year[48]. - The net cash flow from operating activities increased by 45.72% to approximately ¥690.55 million, up from ¥473.87 million in the previous year[48]. - The company reported a total revenue from sales of goods and services of ¥1,239,656,703.63, compared to ¥872,377,407.86 in the previous year, marking an increase of approximately 42.1%[176]. Risks and Challenges - There were no significant risks that materially affected the company's production and operations during the reporting period[7]. - The company faces risks from intensified market competition and policy changes affecting the OTC industry[70]. - The company has sufficient inventory to mitigate the impact of raw material price fluctuations observed during the pandemic[70]. - The company faced production and operational risks due to COVID-19, including increased logistics and labor costs, but has adapted by implementing flexible work arrangements and online marketing strategies[73]. - The company has noted a significant contribution of TCM in treating COVID-19, which has led to increased trust and support from the government for the TCM industry[73]. Investments and Capital Expenditures - The company plans to invest ¥566 million in the construction of a modern production base for traditional Chinese medicine, with the project already in the planning and design phase[43]. - The company established Jiangzhong E-commerce with a registered capital of 5 million yuan to seize e-commerce opportunities, fully owned by the company[33]. - The company invested in Jiangzhong Jihai Pharmaceutical with a registered capital of 150 million yuan, holding a 51% indirect stake[33]. Product Development and Market Strategy - The company launched new products including Jiangzhong Lihuo probiotics and Rui Jie disinfecting wipes in May[27]. - The company has not disclosed any new product or technology developments in this report[6]. - The company is focusing on developing new products, including probiotics and disinfectant wipes, to better cater to the domestic market[44]. - The company aims to enhance its product offerings in the gastrointestinal medication sector and strengthen channel cooperation through large-scale public relations and consumer interaction activities[44]. Environmental and Social Responsibility - Jiangzhong Pharmaceutical has not experienced any environmental pollution incidents or received administrative penalties during the reporting period[111]. - The company has committed to sustainable development, adhering to ecological civilization principles and environmental protection[132]. - The company invested CNY 20,000 for visiting and comforting impoverished households during the Spring Festival[102]. - The company helped sell over CNY 200,000 worth of unsold agricultural products during the pandemic[103]. - The company secured CNY 300,000 in special poverty alleviation funds from the Agricultural Development Bank of China[109]. Shareholder Information - The total number of ordinary shares increased from 525,000,000 to 630,000,000, representing a 20% increase due to a cash dividend of 3 RMB per 10 shares and a stock bonus of 2 shares for every 10 shares held[137]. - The total number of shareholders reached 36,706 by the end of the reporting period[138]. - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group, holds 271,071,486 shares, accounting for 43.03% of total shares[140]. Compliance and Governance - The company has confirmed that there are no non-operating fund occupations by controlling shareholders and their related parties[7]. - There are no violations of decision-making procedures for providing guarantees to external parties[7]. - The company has committed to resolving existing competition issues with Jiangzhong Pharmaceutical within five years from February 26, 2019[84]. - The company guarantees to maintain the independence of Jiangzhong Pharmaceutical and not to interfere with its operational decisions[90].

Group 1: Event Announcement - Jiangzhong Pharmaceutical Co., Ltd. will participate in the "High-Quality Communication for High-Quality Development" investor reception day on July 17, 2020 [1] - The event will take place from 15:00 to 17:00 [1] - Investors can access the online communication platform at http://rs.p5w.net [1] Group 2: Attendees - The attendees include General Manager Mr. Cai Xinping, Chief Financial Officer Mr. Li Xiaojun, and Board Secretary Ms. Tian Yongjing [1] Group 3: Investor Engagement - The company encourages active participation from investors [1] - The announcement emphasizes the importance of transparency and communication regarding the company's situation, development strategy, and sustainable growth [1]

Financial Performance - Net profit attributable to shareholders of the listed company was CNY 131,424,924.09, an increase of 3.44% year-on-year[10]. - Operating income for the first quarter was CNY 525,279,630.39, down 2.23% from the same period last year[10]. - Revenue from over-the-counter drugs was CNY 437,696,076.83, a decrease of 3.14% year-on-year[17]. - Revenue from prescription drugs increased by 21.42% to CNY 69,948,554.85[17]. - Total operating revenue for Q1 2020 was $525.28 million, a decrease of 2.3% from $537.29 million in Q1 2019[61]. - Q1 2020 total profit was approximately ¥133.95 million, a decrease of 4.7% from ¥140.27 million in Q1 2019[68]. Cash Flow - The net cash flow from operating activities increased by 87.12% to CNY 155,522,193.97 compared to the previous year[10]. - Net cash flow from operating activities for the period was 155.52 million RMB, an increase of 72.41 million RMB, representing a growth of 87.12% compared to the same period last year[26]. - Q1 2020 cash flow from operating activities was ¥155.52 million, significantly up from ¥83.12 million in Q1 2019, representing an increase of 87.0%[73]. - The total cash inflow from operating activities was ¥391,668,136.76 in Q1 2020, compared to ¥313,863,527.14 in Q1 2019, marking an increase of about 25%[75]. - The cash outflow from operating activities decreased to ¥229,909,117.78 in Q1 2020 from ¥251,735,294.02 in Q1 2019, showing a reduction of approximately 9%[75]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,691,593,477.87, a decrease of 1.42% compared to the end of the previous year[10]. - Other current assets at the end of the period amounted to 6.41 million RMB, a decrease of 50.23 million RMB, representing a decline of 88.69% compared to the end of the previous year[23]. - Accounts payable at the end of the period amounted to 33.52 million RMB, a decrease of 22.79 million RMB, representing a decline of 40.47% compared to the end of the previous year[23]. - Total liabilities decreased from 834,837,147.96 to 632,973,192.84, a decline of around 24.1%[51]. - Current liabilities decreased significantly from 748,912,845.10 to 549,372,684.08, a reduction of approximately 26.7%[49]. Shareholder Information - The total number of shareholders at the end of the reporting period was 38,411[18]. - The company aims to optimize management and enhance marketing capabilities to mitigate the impact of the pandemic on operations[12]. - The company plans to maintain operational targets despite challenges posed by the pandemic[12]. Investment and Financial Activities - The company has entrusted 50 million RMB in structured deposits with various banks, with annualized returns ranging from 1% to 3.9%[31]. - The company confirmed investment income of 150,000 RMB from entrusted loans as of the end of the reporting period[27]. - The company reported a financial expense of -4.77 million RMB, a decrease of 1.89 million RMB, representing a decline of 65.35% compared to the same period last year[26]. - Other income for the period was 2.06 million RMB, a decrease of 8.35 million RMB, representing a decline of 80.17% compared to the same period last year[26]. Research and Development - Research and development expenses for Q1 2020 were $8.80 million, down from $10.50 million in Q1 2019[61]. - Q1 2020 R&D expenses were ¥8.80 million, an increase of 19.8% compared to ¥7.35 million in Q1 2019[68].

Financial Performance - The company's operating revenue for 2019 was CNY 2,449,404,442.61, representing a 39.55% increase compared to CNY 1,755,229,022.31 in 2018[27]. - The net profit attributable to shareholders for 2019 was CNY 463,596,527.40, a decrease of 1.41% from CNY 470,248,224.88 in 2018[27]. - The net cash flow from operating activities increased by 31.86% to CNY 641,177,784.05 in 2019 from CNY 486,245,960.63 in 2018[27]. - The total assets at the end of 2019 were CNY 4,759,193,757.25, reflecting a 24.69% increase from CNY 3,816,971,960.48 at the end of 2018[27]. - The basic earnings per share for 2019 was CNY 0.88, down 2.22% from CNY 0.90 in 2018[30]. - The weighted average return on equity for 2019 was 13.63%, a decrease of 1.62 percentage points from 15.25% in 2018[30]. - The company reported a net profit of CNY 81,961,392.59 for Q4 2019, down from CNY 129,633,399.68 in Q3 2019[31]. - The company's total net assets attributable to shareholders increased by 9.45% to CNY 3,560,628,579.69 at the end of 2019 from CNY 3,253,296,386.76 at the end of 2018[27]. - The company achieved a revenue of 2.449 billion yuan, representing a year-on-year growth of 39.55%[52]. - The net profit attributable to the parent company was 464 million yuan, a decrease of 0.07 million yuan, or 1.41% year-on-year[42]. Dividend and Share Capital - The proposed profit distribution plan includes a cash dividend of 3 RMB per 10 shares, totaling 157.5 million RMB, which represents 33.97% of the net profit attributable to shareholders[6]. - The total share capital will increase from 52.5 million shares to 63 million shares after a stock bonus of 2 shares for every 10 shares held[6]. - Since 1999, the company has distributed a total of 1.53 billion RMB in cash dividends, representing nearly 45% of net profits during that period[178]. - The company has not proposed a cash profit distribution plan despite having positive profits available for distribution to ordinary shareholders[180]. Audit and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The company has a commitment to ensuring the accuracy and completeness of its financial reports[4]. - The company appointed Ernst & Young Hua Ming as the new auditor for the 2019 fiscal year, replacing Da Xin Accounting Firm after six years of service[193]. - The remuneration for the new auditor Ernst & Young Hua Ming is set at 75 million, compared to 50 million for the previous auditor[193]. - The internal control audit will also be conducted by Ernst & Young Hua Ming, with a fee of 25 million[193]. - The company has not experienced any significant changes in accounting policies or estimates that would impact its financial reporting[192]. - The integrity status of the company and its major stakeholders is reported as good, with no significant debts or court judgments unmet[196]. - The company has no significant litigation or arbitration matters during the reporting period[196]. Operational Highlights - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[8]. - There are no significant risks that materially affect the company's operations during the reporting period[8]. - The company’s registered address is located at 788 Torch Avenue, High-tech Zone, Nanchang, Jiangxi Province[22]. - The company’s stock is listed on the Shanghai Stock Exchange under the code 600750[25]. - The company has a research and development center known as Jiangzhong Pharmaceutical Valley Research Center[15]. - The company’s financial report is available for review in the investment securities department[22]. Market Position and Strategy - The company has established a strong market position, ranking 6th in the pharmaceutical industry with a brand value of 23.736 billion yuan[47]. - The pharmaceutical industry in China saw a revenue of 239.09 billion yuan in 2019, with a year-on-year growth of 7.4%[45]. - The company focuses on quality, safety, and environmental protection in its production processes, adhering to various management systems[51]. - The company is actively exploring e-commerce platforms as a supplementary sales channel[51]. - The company emphasizes the integration of traditional Chinese medicine with modern research and technology to enhance its product offerings[49]. - The company has over 100,000 controllable pharmacy terminals, enhancing its market coverage and brand presence[49]. - The company is committed to continuous product research and development based on traditional Chinese medicine theories[49]. Research and Development - The company invested 47.51 million RMB in R&D, representing a 60.39% increase compared to the previous year[62]. - The company maintained a 100% product quality pass rate throughout the year[59]. - The company received the National Science and Technology Progress Second Prize for key technology research in solid preparation industrialization[58]. - The company has a robust pipeline of patents, including methods for quality control and content determination for its products, ensuring competitive advantage[122]. - The total R&D investment for the company in 2019 was 5,576,000 CNY, representing 2.28% of the operating revenue[134]. - The company plans to focus on the gastrointestinal digestion field in 2020, developing probiotics and functional peptides[140]. - R&D efforts will center on traditional Chinese medicine innovation and product diversification, including probiotics and functional peptides[170]. Acquisitions and Investments - The company made significant investments in its subsidiaries, acquiring 51% stakes in both Sanghai Pharmaceutical and Jisheng Pharmaceutical[48]. - The company completed the acquisition of Sanghai Pharmaceutical and Jisheng Pharmaceutical, leading to an increase in the scope of consolidation and adjustments in the classification of main business[78]. - The company acquired 51% equity in Jiangxi Nanchang Sanghai Pharmaceutical Co., Ltd. for a cash investment of 163.63 million yuan, resulting in a net profit of 22.63 million yuan since the acquisition[156]. - The company also acquired 51% equity in Jiangxi Nanchang Jisheng Pharmaceutical Co., Ltd. for 213.08 million yuan, achieving a net profit of 9.69 million yuan since the acquisition[156]. Challenges and Market Trends - The overall pharmaceutical industry is facing pressures from policy changes, but opportunities exist due to increasing healthcare awareness and an aging population[163]. - The Chinese pharmaceutical industry has experienced a slowdown in growth after maintaining over 10% growth for several years, with the current focus on deepening reforms in healthcare, insurance, and pharmaceuticals[108]. - The COVID-19 pandemic has posed operational challenges, but the company is adapting through flexible work arrangements and strategic planning[173]. - The OTC drug market is becoming increasingly competitive due to ongoing healthcare reforms and the shift of prescription drugs to retail channels[111]. - The integration of retail pharmacies into centralized procurement systems is likely to pressure profit margins, necessitating strategic adjustments for pharmaceutical companies[114]. Future Outlook - The company aims for a revenue growth of approximately 5% in 2020, with an expense ratio around 45%[166]. - The company plans to adapt to policy changes and maximize operational value by closely monitoring the dynamics of the medical insurance directory and procurement policies[113]. - The company plans to leverage its brand advantage to explore the health sector, particularly through protein products and e-commerce sales channels[167]. - The prescription drug business will focus on competitive products like Erhizhi Enteric-Coated Capsules and Ba Zhen Yi Mu Capsules to penetrate grassroots medical services[168]. - The company has implemented a 6S strategic management system to enhance organizational effectiveness and management foundation[170].

Financial Performance - Operating income for the first nine months rose by 31.90% to CNY 1,703,612,827.72 year-on-year[18] - Net profit attributable to shareholders increased by 7.92% to CNY 381,635,134.81 compared to the same period last year[18] - Basic earnings per share increased by 8.96% to CNY 0.73[20] - Total revenue for the first three quarters of 2019 reached RMB 1,703,612,827.72, a 32% increase from RMB 1,291,549,708.18 in the same period of 2018[61] - Net profit for the first three quarters of 2019 was RMB 2,444,689,391.44, compared to RMB 2,301,480,318.23 in 2018, reflecting a growth of approximately 6.2%[60] - The net profit for Q3 2019 was CNY 133,499,477.02, an increase from CNY 125,289,147.95 in Q3 2018, representing a growth of approximately 1.0%[68] - Total profit amounts to 149,902,345.62 CNY, up from 111,233,772.74 CNY, indicating a growth of about 34.8%[76] Cash Flow - Cash flow from operating activities surged by 70.95% to CNY 641,681,356.55 year-on-year[18] - The net cash flow from operating activities for the period was 641.68 million RMB, an increase of 70.95% compared to the same period last year, mainly due to an increase in bank acceptance bill collections[34] - Cash inflow from investment activities totals 1,356,757,911.31 CNY, significantly higher than 43,504,082.70 CNY previously, marking a substantial increase[82] - Cash outflow from investment activities is 1,892,713,444.75 CNY, compared to 108,749,358.10 CNY in the previous period, indicating a significant rise in investment expenditures[82] - The net cash flow from investment activities is -535,955,533.44 CNY, worsening from -65,245,275.40 CNY previously, reflecting increased investment outflows[82] - Total cash inflow from operating activities reached CNY 1,340,504,541.37, up from CNY 1,161,869,000.26 year-over-year[84] - Cash outflow from operating activities decreased to CNY 741,136,316.21 from CNY 832,302,133.74, reflecting improved operational efficiency[84] Assets and Liabilities - Total assets increased by 18.03% to CNY 4,505,320,439.77 compared to the end of the previous year[18] - The company's current assets totaled CNY 2,841,185,125.50, up from CNY 2,293,747,071.49 in the previous year, indicating a growth of approximately 23.9%[46] - The total liabilities of the company were CNY 633,228,513.93, compared to CNY 563,530,666.77 in the previous year, reflecting an increase of about 12.3%[52] - The total equity attributable to shareholders of the parent company rose to CNY 3,516,156,638.57 from CNY 3,253,296,386.76, marking an increase of approximately 8.1%[52] - The total liabilities decreased to RMB 292,760,731.91 from RMB 363,524,950.67, a reduction of about 19.5%[58] - Total liabilities amounted to 363,524,950.67, with current liabilities at 253,725,292.30[103] Investments and Acquisitions - The company completed acquisitions of Sanghai Pharmaceutical and Jisheng Pharmaceutical, leading to an increase in the scope of consolidation[26] - The company's goodwill at the end of the period was 17.79 million RMB, resulting from the difference between the acquisition price of subsidiaries and the fair value of identifiable net assets at the acquisition date[34] - The company reported a significant increase in long-term equity investments, rising to RMB 631,566,583.29 from RMB 259,477,560.52, marking a growth of approximately 143%[58] - The company received CNY 480,939,927.52 from investment recoveries, significantly up from CNY 52,670,000.00 in the previous year[84] Research and Development - The company's revenue from operations increased significantly due to the expanded consolidation scope, with R&D expenses rising to 29.94 million RMB, a growth of 100.54% year-on-year[34] - Research and development expenses for the first three quarters of 2019 were RMB 29,937,720.60, significantly higher than RMB 14,928,837.48 in the same period of 2018, reflecting an increase of about 100%[61] - Research and development expenses for Q3 2019 amounted to CNY 9,840,382.47, which is a significant increase from CNY 6,266,437.49 in Q3 2018, marking a rise of about 57.5%[73] Regional Performance - Revenue from non-prescription drugs reached CNY 1,323,162,321.27, with a growth of 18.55% year-on-year[24] - Revenue from the East China region grew by 43.81% to CNY 479,689,577.93 compared to the previous year[27] Other Financial Metrics - The gross margin for the pharmaceutical industry segment was 67.30%, a decrease of 0.57 percentage points compared to the previous year[22] - The weighted average return on net assets decreased by 0.35 percentage points to 11.26%[20] - The company reported a significant increase in minority shareholders' equity, which reached 355.94 million RMB, up 35.58 million RMB from the previous year, primarily due to the recognition of minority interests from subsidiaries acquired during the period[34] - The company distributed dividends totaling CNY 147,000,000.00, an increase from CNY 135,000,000.00 in the previous year[86]

Financial Performance - The company's operating revenue for the first half of 2019 was approximately RMB 1.14 billion, representing a 27.44% increase compared to the same period last year[22]. - The net profit attributable to shareholders of the listed company was approximately RMB 252 million, an increase of 10.35% year-on-year[22]. - The net cash flow generated from operating activities reached approximately RMB 474 million, showing a significant increase of 114.27% compared to the previous year[22]. - Basic earnings per share for the reporting period were RMB 0.48, up 11.63% from RMB 0.43 in the same period last year[22]. - The company reported a diluted earnings per share of RMB 0.48, consistent with the basic earnings per share[22]. - The total comprehensive income for the first half of 2019 was ¥259,080,269.64, compared to ¥228,346,258.86 in the same period of 2018, indicating an increase of 13.5%[161]. - The company reported a total equity of ¥3,493,581,751.92, up from ¥3,371,960,306.56, representing a growth of 3.6%[156]. Assets and Liabilities - The total assets of the company at the end of the reporting period were approximately RMB 4.36 billion, a 14.19% increase from the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were approximately RMB 3.39 billion, reflecting a 4.10% increase compared to the previous year[22]. - Total liabilities amounted to approximately $619.88 million, compared to $563.53 million, showing an increase of about 10%[148]. - The company's total liabilities at the end of the current period were 2,318,101,763.59 CNY[197]. Investments and Acquisitions - The company acquired 51% stakes in both Sanghai Pharmaceutical and Jisheng Pharmaceutical, expanding its consolidation scope[38]. - The company completed the acquisition of 51% stakes in Jiangxi Nanchang Sanghai Pharmaceutical for CNY 163,631,203.03, contributing a net profit of CNY 11,770,000 since consolidation[65][68]. - The acquisition of 51% stakes in Jiangxi Nanchang Jisheng Pharmaceutical was finalized for CNY 213,081,642.00, with a net profit of CNY 4,600,000 since consolidation[65][68]. Research and Development - Research and development expenses surged by 132.01% to 20,097,338.13 RMB, up from 8,662,399.99 RMB, indicating increased investment in innovation[49]. - The company is actively pursuing research and development in the gastrointestinal field, with ongoing studies on key products like Xiao Chai Hu Granules and Erythromycin Enteric-Coated Capsules[44]. Market and Competition - The implementation of the "4+7" centralized procurement policy is expected to intensify competition in the medical terminal market[37]. - The company plans to enhance new product development and marketing strategies to address intensified market competition and regulatory pressures[76]. Environmental Responsibility - The company was awarded the second China Ecological Civilization Award, becoming the first manufacturing enterprise to receive this honor[109]. - No environmental pollution incidents occurred during the reporting period, and the company did not face any administrative penalties from environmental protection authorities[109]. - The company has established a wastewater treatment station at Sanghai Pharmaceutical, with a chemical oxygen demand discharge concentration of 259.68 mg/L and a total discharge of 4.155 tons in the first half of 2019[113]. Social Responsibility - The company helped the impoverished village of Nanzhou achieve poverty alleviation, reducing the poverty incidence from 4.97% in 2014 to 0.6%[101]. - Total investment in poverty alleviation during the reporting period amounted to 816,000 RMB, including 800,000 RMB in funds and 16,000 RMB in material donations[102]. - The company plans to continue its poverty alleviation efforts by combining financial support with capacity building and enhancing local economic development[105]. Shareholder Information - The total share capital increased from 420 million shares to 525 million shares after the implementation of the 2018 profit distribution plan[24]. - The company distributed cash dividends of 3.5 RMB per 10 shares and issued 2.5 bonus shares for every 10 shares held[133]. - The top shareholder, China Resources Jiangzhong Pharmaceutical Group, holds 225,892,905 shares, accounting for 43.03% of total shares[135].

证券代码：600750 证券简称：江中药业 公告编号：2019-034 江中药业股份有限公司 | --- | --- | |----------------------------------------------------------------------|------------------------------| | 关于参加 2019 | 年投资者集体接待日活动的公告 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融 资计划、股权激励、可持续发展等投资者所关心的问题，江中药业股份有限公 司（以下简称"公司"）定于 2019 年 6 月 26 日下午 15:30—17:00 参加由江西 省上市公司协会联合深圳市全景网络有限公司举办的主题为"真诚沟通 规范发 展 互利共赢"江西上市公司 2019 年投资者集体接待日活动。现将有关事项公 告如下： 本次集体接待日网上交流网址：投资者可以登录 http://rs.p5w.n ...

Financial Performance - Operating revenue rose by 16.72% to CNY 537,286,600.72 year-on-year[10] - Net profit attributable to shareholders increased by 9.50% to CNY 127,051,494.49 compared to the same period last year[10] - Total operating revenue for Q1 2019 was $537.29 million, an increase of 16.73% compared to $460.33 million in Q1 2018[49] - Net profit for Q1 2019 reached $130.42 million, representing a 12.00% increase from $116.07 million in Q1 2018[51] - The company's operating revenue for Q1 2019 was CNY 358,714,259.57, a decrease of 2.4% compared to CNY 367,595,695.75 in Q1 2018[55] - The net profit for Q1 2019 reached CNY 118,980,074.50, representing an increase of 17.3% from CNY 101,419,341.73 in Q1 2018[57] Assets and Liabilities - Total assets increased by 14.66% to CNY 4,376,403,909.88 compared to the end of the previous year[10] - Total liabilities rose to ¥645,819,660.87 from ¥563,530,666.77, which is an increase of about 14.6%[39] - Current assets increased to ¥2,709,626,600.93 from ¥2,293,747,071.49, representing a growth of approximately 18.1% year-over-year[32] - The total assets of the company amounted to 3,816,971,960.48 RMB, with current assets totaling 2,293,747,071.49 RMB[70] - Total liabilities amounted to ¥563,530,666.77, with current liabilities at ¥453,731,008.40 and non-current liabilities at ¥109,799,658.37[71] Cash Flow - Cash flow from operating activities decreased by 21.70% to CNY 83,115,380.42 compared to the previous year[10] - The net cash flow from operating activities for the current period is RMB 83.12 million, a decrease of RMB 23.04 million, reflecting a decline of 21.70% due to increased tax payments compared to the previous year[24] - The cash flow from operating activities for Q1 2019 was CNY 83,115,380.42, a decrease of 21.7% compared to CNY 106,155,123.61 in Q1 2018[62] - Total cash inflow from operating activities was 313,863,527.14 RMB, while cash outflow was 251,735,294.02 RMB, resulting in a positive cash flow from operations[64] Research and Development - The research and development expenses for the current period amount to RMB 10.50 million, an increase of RMB 6.44 million, representing a growth rate of 158.78% due to increased R&D investment and expanded consolidation scope[24] - Research and development expenses increased to $10.50 million in Q1 2019, up 159.99% from $4.06 million in Q1 2018[49] - Research and development expenses increased to CNY 7,346,560.15 in Q1 2019, up 81.5% from CNY 4,055,944.18 in Q1 2018[55] Acquisitions and Investments - The company completed the acquisition of Sanhai Pharmaceutical and Jisheng Pharmaceutical, expanding its operational scope[14] - The company completed the acquisition of 51% equity in Sanghai Pharmaceutical and Jisheng Pharmaceutical, which has been included in the consolidation scope since February 2019[25] - The balance of goodwill at the end of the period is RMB 15.84 million, resulting from the difference between the consideration paid for the acquisition of subsidiaries and the fair value of identifiable net assets[21] Equity and Shareholders - The company reported a weighted average return on equity of 3.83%, a decrease of 0.07 percentage points from the previous year[10] - The balance of minority shareholders' equity at the end of the period is RMB 350.24 million, an increase of RMB 350.09 million, primarily due to the recognition of minority interests from the acquisition of Sanghai Pharmaceutical and Jisheng Pharmaceutical[24] - Total equity attributable to shareholders reached ¥3,253,296,386.76, with retained earnings of ¥2,182,409,430.23[71] Regional Performance - Revenue from the South China region grew by 30.50% compared to the previous year[16] - Revenue from the prescription drug category saw a significant increase of 330.99% due to the acquisition of subsidiaries[12] Financial Standards and Reporting - The company executed new financial instrument standards starting January 1, 2019, adjusting the classification of certain financial assets[75] - The company also adopted new revenue standards from January 1, 2019, reporting advance receipts from sales in "contract liabilities"[75] - The audit report is not applicable for the current period[82]